A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss

Read full story on CNBC Markets
Share
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
AI disclosure

Summary

Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic.

Original reporting

Open original source

Related coverage

Read full article on CNBC Markets

Get the AFBytes Brief

Major stories, AI-assisted analysis, and what to watch next. Free, monthly, unsubscribe anytime.